论文部分内容阅读
目的:观察DNA拓扑异构酶Ⅱ(TOPOⅡ)在食管癌的表达,初步探讨其临床生物学意义。方法:应用S-P免疫组织化学方法检测原发性食管癌103例,其中鳞状细胞癌100例,腺癌3例和癌周正常黏膜组织32例TOPOⅡ的表达。结果:TOPOⅡ在食管癌的表达明显高于癌周组织,癌周鳞状上皮基细胞可见少数核阳性表达。鳞状细胞癌高于腺癌的表达。食管鳞状细胞癌的分化程度与TOPOⅡ的表达呈正相关。结论:TOPOⅡ在食管癌周的表达早于食管癌分生过程中的细胞形态变化,可能成为食管癌发生的早期标志物。TOPOⅡ食管癌表达低,符合其比食管鳞状细胞预后差,对放疗、化疗不敏感的事实。TOPOⅡ在高中分化食管鳞状细胞癌的表达低分化者,提示食管癌高分化者对拓扑异构酶抑制剂化疗药敏感、预后好。
Objective: To observe the expression of topoisomerase Ⅱ (TOPOⅡ) in esophageal cancer and to explore its clinical significance. Methods: The expression of TOPO Ⅱ in 103 cases of primary esophageal cancer, including 100 cases of squamous cell carcinoma, 3 cases of adenocarcinoma and 32 cases of normal mucosa tissues were detected by S-P immunohistochemistry. Results: The expression of TOPO Ⅱ in esophageal cancer was significantly higher than that in peri-cancerous tissues. Squamous cell carcinoma is higher than adenocarcinoma. Esophageal squamous cell carcinoma differentiation and TOPO Ⅱ expression was positively correlated. Conclusion: The expression of TOPOⅡ in esophageal cancer is earlier than that in esophageal cancer during the process of esophageal cancer and may be an early marker of esophageal cancer. TOPO Ⅱ esophageal cancer expression is low, consistent with its poor prognosis of esophageal squamous cells, radiotherapy and chemotherapy is not sensitive to the fact. TOPO Ⅱ differentiated in high school differentiation of esophageal squamous cell carcinoma of poorly differentiated, suggesting that highly differentiated esophageal cancer chemotherapy topoisomerase inhibitor sensitivity and good prognosis.